Investor Relations

Zuckerberg Gives a Nod to Skin Cancer Detection Apps Industry

May 1, 2016

You read that correctly! In a speech last month, Mark Zuckerberg acknowledged Skin Cancer Detection apps as one of the notable leaders using Artificial Intelligence for the future of health care. Detecting Melanoma early can mean the difference between life and death for anyone who uses our app.

It’s no secret that A.I. will play a larger role in the future of health care. To be recognized by another technological leader this early is a huge honor.

Read the Full Story on Forbes.com
Learn More About Our Stock Offering

Investor Relations

Emerald Medical Applications is a privately held startup that operates in the field of image processing software infrastructure solutions for an extensive range of applications for medical unmet needs.

The first solution developed by Emerald is Derma Compare, a revolutionary melanoma-screening platform.

Emerald has a staff of 14 talented technology, marketing and operation people working tirelessly toward a vision of better health and diagnosis globally.

 

The Market Opportunity

420 million people around the world are part of the high-risk population for Melanoma – North and South America, Europe, Australia, South Africa and Israel.

The US alone spends more than $8B every year for the treatment of melanoma. In Germany, it is the most common cancer dubbed as “Nation-Cancer”.

There is still no cure for melanoma. To treat one melanoma patient costs more than $150,000 per annum– so the only viable way to save lives is early detection. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. Australia and New Zealand have the highest rates of melanoma in the world.

OTCQB:MRLA

Business Description

Emerald Medical Applications Corp. (OTCQB: MRLA), f/k/a Zaxis International Inc., a Delaware corporation (the “Registrant”), effective July 14, 2015, completed a Share Exchange Agreement with Emerald Medical Applications Ltd, an Israeli company, which became the Registrant’s wholly-owned subsidiary. Emerald is engaged in the business of commercially exploiting its proprietary “DermaCompare” technology for the early detection of skin cancer using unique, cloud-based software.

Emerald has entered into several distgribution agreements and has already commenced marketing activity of its DermaCompare Technology directly to medical professionals and facilities in Italy, Netherlands, Sweden, Israel, Australia and New Zealand. Emerald is continuing to negotiate for additional distribution agreements throughout Europe, North America, Asia and elsewhere.

The DermaCompare Technology is designed to revolutionize the diagnosis and early detection of skin cancer thereby significantly reducing mortality. The DermaCompare platfor quickly analyzies the patient’s skin condition data which is transmitted to the physician in real-time, thereby pdermitting the physician to complete evaluation and diagnosis of the presence or absence of skin cancer. Emerald is continuing development of next generation enhancements of its technology.

The major target markets for DermaCompare include HMOs, insurance companies, medical centers, dermatologist groups and medical research institutes. In furtherance of its ongoing business plan, Emerald has established relationships with several public and private medical centers and clinics as well as with a leading University Medical Center in Israel.

OTC Disclosure & News Service:

http://www.otcmarkets.com/stock/MRLA/filings

http://www.otcmarkets.com/stock/MRLA/news

Forward looking statement:

The Company believes that some of the statements included in this release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company’s ability to obtain contracts and accurately estimate net revenues due to variability in size, scope and duration of contracts. Further information on potential factors that could affect the Company’s financial results, can be found in the Company’s various filings with the Securities and Exchange Commission (SEC). Statements included in this release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company’s ability to obtain contracts and accurately estimate net revenues due to variability in size, scope and duration of contracts. Further information on potential factors that could affect the Company’s financial results, can be found in the Company’s various filings with the Securities and Exchange Commission (SEC).The Company believes that some of the statements included in this release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company’s ability to obtain contracts and accurately estimate net revenues due to variability in size, scope and duration of contracts. Further information on potential factors that could affect the Company’s financial results, can be found in the Company’s various filings with the Securities and Exchange Commission (SEC).